Navigation Links
New One-Year Pharmacoeconomic Study Shows Avonex is Cost-Effective,Relative to Other Interferon Therapies for Multiple Sclerosis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 13, 2007 - Biogen Idec Inc. (NASDAQ: BIIB) announced today that one-year data presented at the Academy of Managed Care Pharmacy's (AMCP) 2007 Annual Meeting show that AVONEX(R) (Interferon beta-1a) is a cost-effective therapy in multiple sclerosis (MS) when compared to other interferon beta treatments. Using a comprehensive analysis of medical and pharmacy costs, the results of the research concluded that patients treated with AVONEX, the most prescribed MS therapy worldwide, have the lowest total one-year cost to a health plan when compared to other interferon beta treatments.

Researchers analyzed 10,622 patients over one year to assess how demographic, administrative and clinical variables affect MS costs and utilization patterns and to examine the economic impact of treating MS. The independent data contained in Multiple Sclerosis Benchmarks(TM)(1), the retrospective, claims-based, observational study, showed that patients treated with AVONEX had the lowest average one-year cost compared to patients receiving other interferon beta treatments. It has been estimated that the total annual economic burden of MS in the United States exceeds $6.8 billion with a lifetime cost of $2.2 million per patient.(2)

"MS is a disease that can have an impact beyond its debilitating effect on patients," said Michael Pollock, Vice President, Global Health Economics, Biogen Idec. "Cost-effectiveness is an increasingly important factor in treating chronic diseases like MS. This study shows that in addition to its clinical impact, AVONEX can also help to substantially reduce the cost of care for patients living with this disease, when compared to other interferon beta treatments."

The MS Benchmarks analysis showed the total costs over one-year to MS patients on interferon beta therapy were: AVONEX, $19,896.15; Rebif(R) (Interferon beta-1a) sc, $22,207.85; and Betaseron(R) (Inter
'"/>




Page: 1 2 3

Related medicine technology :

1. Acuity One-Year Findings Meet All Primary Endpoints in Favor of Angiomax (Bivalirudin) Alone Treatment Group
2. First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone Was More Cost-Effective Than Interferon Beta Therapies for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
5. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
Post Your Comments:
(Date:11/26/2014)... LA JOLLA, Calif. , Nov. 26, 2014 /PRNewswire/ ... ), a biopharmaceutical company leading the discovery and development ... Kleanthis G. Xanthopoulos , Ph.D., President and CEO of ... th Annual Piper Jaffray Healthcare Conference at the ... at 2:00 p.m. EST.  The presentation will be webcast ...
(Date:11/26/2014)... ST. LOUIS , Nov. 26, 2014 Scott ... has seen most of the world. As an engineer for the ... was a member of the military service. He,s been to six ... life. Photo - http://photos.prnewswire.com/prnh/20141126/161076 Photo - ... product specifically for travelers, he has a pretty good idea of ...
(Date:11/26/2014)... , Nov. 26, 2014  CARsgen, a leader ... cell immunotherapy to treat a variety of cancers, today ... by BVCF, a China -based healthcare ... immunotherapy company focused on the development of new therapeutics ... with Shanghai Cancer Institute and Shanghai Renji Hospital, the ...
Breaking Medicine Technology:Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 2Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 3Steiger Has Created the First Pill Case Specifically Designed For Travel 2CARsgen Completes Series A Financing 2
(Date:11/27/2014)... In a world enveloped in ... has lessened, and due to the intrusion of ... sleep has eroded. According to Web MD, one ... (Reference: http://www.webmd.com/sleep-disorders/features/sleep-deprivation-workplace ). This remarkably high number ... incalculable amount, leading not only to dissatisfied employers, ...
(Date:11/27/2014)... 2014 An inventor from Buffalo, N.Y., ... of life, and she wants to lessen its impact. ... I decided that there needed to be a way ... Easy to use and producible in design variations, the ... private areas throughout the day. It avoids bad odors, ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 Nearly ... been filed in a consolidated litigation now underway ... , Documents recently updated in the Philadelphia ... in the state proceeding, all of which involve ... and other psychiatric conditions. Many of the cases ...
(Date:11/27/2014)... -- Most babies and young children don,t need medicines ... Drug Administration says. Over-the-counter (OTC) cold and cough ... 2 because they could cause serious and potentially deadly ... about three colds a year, but children get them ... want to give them pain relievers, decongestants and other ...
(Date:11/27/2014)... meals can pose a challenge for people who have ... Many traditional Thanksgiving dishes -- such as turkey, corn, ... "when it comes to pies, stuffing, gravy, etc., gluten-free ... director of the Gluten and Allergic Digestive Disorders program ... said in a center news release. "For those ...
Breaking Medicine News(10 mins):Health News:Research Shows Surprising Number of US Workers Affected by Lack of Sleep 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:Expert Shares Gluten-Free Thanksgiving Tips 2
... ptient with a turbocharger for the heart called C-Pulse.// ... moderate heart problems, who are still not ill enough to ... These patients may be those who may feel extreme tiredness, ... help from medications. ,The new device is a balloon ...
... may have less tolerance to alcohol intakes than men, suggests ... 2005//. ,Researchers of University of Pittsburgh School of Medicine ... things to women than their male counterparts. Women may be ... men even if they have the same amount of the ...
... colonoscopy may be the favorable method to screen women// ... cancer, flexible sigmoidoscopy is used to detect colorectal neoplasias, ... dysplasia, or cancer. Researchers had used colonoscopy to detect ... women who were referred for colon-cancer screenings. ,Of the ...
... that extracts of the grapefruit seeds contain antioxidants ... a fruit, grapefruit had been associated with acidity ... and helpful ingredients that have healing properties. Researchers ... and presented their study findings at the Digestive ...
... research presented at Digestive Disease Week 2005, antidepressants ... depression, also known as unipolar depression, is often ... inhibitors (SSRIs) by physicians. , ,Previous research ... (NSAID) can cause increased bleeding and hemorrhage in ...
... Baptist Medical Center, US, have found that low doses ... and thus limits the side effects of the therapy ... chemotherapy given to children suffering from Acute Lymphblastic Leukemia ... cancer were administered very limited dosage of chemotherapy and ...
Cached Medicine News:
... highest g-force ever. But optimal productivity in ... MAX combines maximum force, capacity, and ease ... worlds apart from any other system. With ... efficiency, Optima takes productivity to the MAX. ...
... ultracentrifuge is designed to play a ... if research involves proteomics, cytomics or ... computer, enhanced firmware, powerful Optima eXPert ... Optima L-XP delivers superior functionality, optimized ...
... The Dimension Xpand integrated chemistry ... compact footprint to the smaller laboratory. ... The Dimension Xpand integrated chemistry system ... tailored for the low-volume environment, in ...
The Express Plus clinical chemistry analyzer is a fully automated walk away system designed for maximum productivity, convenience and reliability....
Medicine Products: